Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

KEYNOTE-361 Investigators

    Research output: Contribution to journalArticlepeer-review

    345 Scopus citations

    Fingerprint

    Dive into the research topics of 'Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.

    Medicine & Life Sciences